Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimonabant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 8/20 | 1.00 |
| ▸ | CNR2 | P34972 | 4/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.98 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | HRH2 | P25021 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.98 |
| ▸ | CCKAR | P32238 | 1/20 | 0.98 |
| ▸ | CCKBR | P32239 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimonabant SCHEMBL1186698 | 1.00 | CNR1 (1.00) | CNR1CNR2ACHECYP2C9GPR55 | |
| Rimonabant SCHEMBL29373177 | 0.99 | CNR1 (1.00) | CNR1CNR2ACHECYP2C9GPR55 | |
| Rimonabant SCHEMBL38637 | 0.99 | CNR1 (1.00) | CNR1CNR2ACHECYP2C9GPR55 | |
| SCHEMBL12053639 | 0.98 | CNR1 (0.98) | CNR1CNR2ACHECYP2C9GPR55 | |
| Rimonabant SCHEMBL746112 | 0.97 | CNR1 (0.96) | CNR1CNR2ACHECYP2C9GPR55 | |
| Rimonabant SCHEMBL8742390 | 0.96 | CNR1 (0.94) | CNR1CNR2ACHECYP2C9GPR55 | |
| Rimonabant SCHEMBL8742211 | 0.95 | CNR1 (0.93) | CNR1CNR2ACHECYP2C9GPR55 | |
| SCHEMBL14397516 | 0.95 | CNR1 (0.92) | CNR1CNR2ACHECYP2C9GPR55 | |
| SCHEMBL29386088 | 0.94 | CNR1 (1.00) | CNR1CNR2ACHECYP2C9GPR55 | |
| SCHEMBL3816361 | 0.94 | CNR1 (0.91) | CNR1CNR2ACHECYP2C9GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022204419-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| WO-2022204414-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-4539845-A1 | PERIPHERALIZATION OF CENTRALLY-ACTING CANNABINOID-1 RECEPTOR ANTAGONISTS BY NANOPARTICLES FOR THE TREATMENT METABOLIC RELATED CONDITIONS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023242843-A1 | PERIPHERALIZATION OF CENTRALLY-ACTING CANNABINOID-1 RECEPTOR ANTAGONISTS BY NANOPARTICLES FOR THE TREATMENT METABOLIC RELATED CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-12-21 | — | — | WO | disclosed |
| WO-2022204419-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204414-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | disclosed |